immunoglobulin A nephropathy
Conditions
Interventions
Experimental group:leflunomide 20mg/d
Sponsors
West China Hospital of Sichuan University
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1.Aged between 18 to 65 years; 2. 24 hrs proteinuria of more than 1.0g, but less than 3.0 g; 3.CKD stage range from 1 to 3; 4. No steroid or immunosuppressor used before.
Exclusion criteria
Exclusion criteria: 1. Secondary IgA nephropathy such as Henoch-Schonlein purpura, ankylosing spondylitis, psoriatic arthritiswith spondyloarthropathy, chronic alcoholic cirrhosis; 2. Combine with other kidney injury: Diabetic Nephropathy, obesity related glomerulopathy, interstitial nephritis and so on; 3. obvious liver dysfunction (transaminase three times above normal) or the abnormal of coagulation, lower WBC (less than 2*10^9); 4. pregnancy or Lactation; 5. Drug sensitivity or drug allergy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 24-h proteinuria;urine red blood cells;glomerular filtration rate;serum creatinine;blood urea nitrogen; | — |
Secondary
| Measure | Time frame |
|---|---|
| WBC;liver function;serum albumin; | — |
Countries
China
Contacts
Public ContactLI ZI
Outcome results
None listed